Washington,
D.C. 20549
FORM
6-K
REPORT
OF
FOREIGN ISSUER
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For
the month of June 2007
Commission
File Number 000-51122
pSivida
Limited
(Translation
of registrant’s name into English)
Level
12 BGC Centre
28
The Esplanade
Perth
WA 6000
Australia
(Address
of principal executive offices)
(Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F).
Form
20-F
ý Form
40-F o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7):
Indicate
by check mark whether the registrant by furnishing the information contained
in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
o No
ý
If
"Yes"
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82- ___.
The
document attached as Exhibit 99.1 to this Report on Form 6-K is hereby
incorporated by reference herein and into the following registration statements:
(i) the Registrant's Registration Statement on Form F-3, Registration
No. 333-132776; (ii) the Registrant's Registration Statement on
Form F-3, Registration No. 333-132777; (iii) the Registrant's
Registration Statement on Form F-3, Registration No. 333-135428; (iv)
the Registrant's Registration Statement on Form F-3, Registration
No. 333-141083; (v) the Registrant's Registration Statement on
Form F-3, Registration No. 333-141091; and (vi) the Registrant's
Registration Statement on Form F-3, Registration
No. 333-143225.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant,
pSivida Limited, has duly caused this report to be signed on its behalf by
the
undersigned, thereunto duly authorized.
Date:
June
28, 2007
| PSIVIDA LIMITED | ||
| By: | /s/ Michael J. Soja | |
|
Michael J. Soja |
||
|
Vice
President, Finance and Chief Financial
Officer
|
||
EXHIBIT
INDEX
|
EXHIBIT
99.1:
|
ASX
Release: pSivida signs evaluation agreement for cardiovascular drug
delivery
|
| ASX/MEDIA RELEASE |
28
June
2007
|
pSivida
signs evaluation agreement for
cardiovascular
drug delivery
Boston,
MA. and Perth, Australia - Global
drug delivery company, pSivida Limited (NASDAQ:PSDV,
ASX:PSD, Xetra:PSI)
announced that it has entered into an evaluation agreement with an undisclosed
large global medical device company to evaluate cardiovascular
delivery of drugs using pSivida’s drug delivery technologies. The agreement
follows the expiration of a previous evaluation agreement with the same
medical
device company.
-ENDS-
Released
by:
|
pSivida
Limited
Brian
Leedman
Vice
President, Investor Relations
pSivida
Limited
Tel:
+ 61 8 9226 5099
brianl@psivida.com
|
US
Public Relations
Beverly
Jedynak
President
Martin
E. Janis & Company, Inc
Tel:
+1 (312) 943 1100 ext. 12
bjedynak@janispr.com
|
European
Public Relations
Eva
Reuter
Accent
Marketing Limited
Tel:
+49 (254) 393 0740
e.reuter@e-reuter-ir.com
|
NOTES
TO EDITORS:
pSivida
is a global bio-nanotech company committed to the biomedical sector and the
development of drug delivery products. Retisert®
is FDA
approved for the treatment of uveitis. Vitrasert®
is FDA
approved for the treatment of AIDS-related CMV Retinitis. Bausch & Lomb owns
the trademarks Vitrasert®
and
Retisert®.
pSivida
has licensed the technologies underlying both of these products to Bausch
&
Lomb. The technology underlying Medidur™
for
diabetic macular edema is licensed to Alimera Sciences and is in Phase III
clinical trials. pSivida
has a worldwide collaborative research and license agreement with Pfizer
Inc.
for other ophthalmic applications of the Medidur™
technology.
pSivida
owns the rights to develop and commercialize a modified form of silicon
(porosified or nano-structured silicon) known as BioSilicon™, which has
applications in drug delivery, wound healing, orthopedics, and tissue
engineering. The most advanced BioSilicon™ product, BrachySil™ delivers a
therapeutic, P32 directly to solid tumors and is presently in Phase II clinical
trials for the treatment of pancreatic cancer.
pSivida’s
intellectual property portfolio consists of 71 patent families, 99 granted
patents, including patents accepted for issuance, and over 300 patent
applications.
pSivida
conducts its operations from facilities near Boston in the United States,
Malvern in the United Kingdom and Perth in Australia.
pSivida
is listed on NASDAQ (PSDV),
the
Australian Stock Exchange (PSD)
and on
the Frankfurt Stock Exchange on the XETRA system (PSI).
pSivida is a founding member of the NASDAQ Health Care Index and the Merrill
Lynch Nanotechnology Index.
This
release contains forward-looking statements that involve risks and uncertainties
including with respect to our ability to raise sufficient funds, our ability
to
capitalize on our technology and intellectual property base or grow our
business, our potential products, including clinical development and trials
of
these potential products and our partnerships. Although we believe that the
expectations reflected in such forward-looking statements are reasonable
at this
time, we can give no assurance that such expectations will prove to be correct.
Given these uncertainties, readers are cautioned not to place undue reliance
on
such forward-looking statements. Actual results could differ materially from
those anticipated in these forward-looking statements due to many important
factors including: the
risk
that we will not be able to raise
additional funds at favorable terms or at all; and the
risk
that this evaluation agreement will not lead to a license agreement with
the
medical device company. Other
reasons are contained in cautionary statements in the Annual Report on Form
20-F
filed with the U.S. Securities and Exchange Commission, including, without
limitation, under Item 3.D, "Risk Factors" therein. We do not undertake to
update any oral or written forward-looking statements that may be made by
or on
behalf of pSivida.